A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors. Issue 4 (August 2020)

• Record Type: Journal Article
• Authors: Deng, Shu-hua; Wang, Zhan-Zhang; Lu, Hao-Yang; Li, Lu; Hu, Jin-Qing; Zhu, Xiu-Qing; Xie, Huan-Shan; Chen, Hong-Zhen; Zhang, Ming; Ni, Xiao-Jia; Qiu, Chang; Shang, De-Wei; Wen, Yu-Guan
• Is Part Of: Therapeutic drug monitoring. Volume 42:Issue 4(2020:Aug.)
• Publication Date: 2020-08
• Subjects: olanzapine -- therapeutic drug monitoring -- valproate -- smoking -- patient-related variables; Pharmacokinetics -- Periodicals; Patient monitoring -- Periodicals; Drugs -- Analysis -- Periodicals; Body fluids -- Analysis -- Periodicals; Drug Therapy -- Periodicals; Monitoring, Physiologic -- Periodicals; Pharmacology -- Periodicals; 615.7
• DOI: 10.1097/FTD.0000000000000738
• Languages: English
• ISSNs: 0163-4356

Abstract

Abstract : Background: The objective of this study was to investigate the serum concentrations of olanzapine in relation to age, sex, and other factors in Chinese patients aged between 10 and 90 years. Methods: Data for 884 olanzapine patients, deposited between 2016 and 2017, were retrieved from the therapeutic drug monitoring database of the Affiliated Brain Hospital of Guangzhou Medical University. The effects of covariates on serum olanzapine concentration, dose-normalized concentration (C/D ratio), and normalized concentration (C/D/weight) were investigated. Results: Generally, male patients had lower olanzapine concentration, C/D ratio, and C/D/weight than female patients ( P < 0.001). Smoking and drinking reduced olanzapine concentration, C/D ratio, and C/D/weight ( P < 0.001). Coadministration with valproate decreased olanzapine concentration, C/D ratio, and C/D/weight by about 16%, 30%, and 40%, respectively ( P < 0.001). Patients younger than 60 years had higher olanzapine concentrations ( P < 0.05) but lower C/D ratios and C/D/weight ( P < 0.001) than patients older than 60 years. Age was correlated with olanzapine concentration (r = −0.082, P < 0.05), C/D ratio (r = 0.196, P < 0.001), and C/D/weight (r = 0.169, P < 0.001). Sample timing after dose and diagnostic factors also contributed to the olanzapine concentrations. Multiple linear regression analysis revealed significant influences of dosage, age, sex, valproate comedication, smoking, postdose interval, and schizophrenia (vs bipolar affective disorders) on serum olanzapine concentrations. Conclusions: The metabolism of olanzapine may be altered by several factors. Patients characterized with a combination of factors may benefit from therapeutic drug monitoring for the adjustment of olanzapine dose to minimize adverse reactions.